CYFRA 21-1 Level Predicts Survival in Lung Cancer Patients
Author Information
Author(s): Barlési F, Tchouhadjian C, Doddoli C, Torre J-P, Astoul P, Kleisbauer J-P
Primary Institution: Assistance Publique Hôpitaux de Marseille
Hypothesis
The study investigates the prognostic value of CYFRA 21-1 in non-small-cell lung cancer patients receiving gefitinib after failure of platinum-containing regimens.
Conclusion
CYFRA 21-1 is a useful tool for predicting the survival of non-small-cell lung cancer patients receiving gefitinib as third-line therapy.
Supporting Evidence
- Multivariate analysis showed a negative impact on survival for CYFRA 21-1 levels higher than 3.5 ng/ml.
- Patients with a skin reaction had a favorable impact on survival.
- The median survival time for patients was 4 months.
Takeaway
Doctors can use a blood test called CYFRA 21-1 to help figure out how long lung cancer patients might live when they are treated with a specific medicine called gefitinib.
Methodology
Serum samples were collected from patients before gefitinib therapy, and multivariate analysis was performed to assess survival impact.
Potential Biases
Potential bias due to the study being conducted in a single center and the exclusion of patients who did not receive gefitinib.
Limitations
The study had a small sample size and was limited to patients who had already failed platinum-based treatments.
Participant Demographics
The median age of participants was 60 years, and all were current or former smokers.
Statistical Information
P-Value
0.02
Confidence Interval
95% CI 1.13–5.29
Statistical Significance
p=0.02
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website